AUTH/3861/12/23 - Complainant v Novartis Pharmaceuticals

Allegations about a third-party conference email

  • Received
    11 December 2023
  • Case number
    AUTH/3861/12/23
  • Applicable Code year
    2021
  • Completed
    23 April 2025
  • No breach Clause(s)
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions
    Advertisement
  • Appeal
    No appeal

Case Summary

This case was in relation to a promotional email sent to a health professional by a third-party medical publisher.

The outcome under the 2021 Code was:

Breach of Clause 2

Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Breach of Clause 5.1 (x2)

Failing to maintain high standards

Breach of Clause 5.5 (x3)

Failing to be sufficiently clear as to the company’s role and involvement

Breach of Clause 11.2 (x2)

Promoting a medicine for an unlicensed indication

Breach of Clause 12.1

Failing to include UK prescribing information

Breach of Clause 12.10

Failing to include a black triangle adjacent to the first mention of the product in digital material

Breach of Clause 15.6 (x4)

Disguising promotional material

 

No Breach of Clause 6.1

Requirement that information must be accurate, up-to-date and not misleading

No Breach of Clause 11.2

Requirement not to promote a medicine for an unlicensed indication

This summary is not intended to be read in isolation.
For full details, please see the full case report below.